MindWalk (HYFT) Stock: Buy, Sell, or Hold?
HYFT - MindWalk Holdings Corp. Common Stock
$1.55
0.06 (4.03%)
▲
5d:
+12.32%
30d:
+17.42%
90d:
+7.64%
WAIT
LOW Confidence
Analysis Updated: Oct 6, 2026 12:00 AM ET
Earnings: Sep 14, 2026
0d
Get Alerted When HYFT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: HYFT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: HYFT shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: HYFT is currently trading at $1.55, which is considered extended relative to its 30-day fair value range of $1.26 to $1.43. From a valuation perspective, the stock is trading at a discount (Forward PE: -8.3) compared to its historical average (85.2). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HYFT is in a downtrend. Immediate support is located at $1.30, while resistance sits at $1.80. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: HYFT scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.33 (+179.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HYFT is in a downtrend. Immediate support is located at $1.30, while resistance sits at $1.80. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: HYFT scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.33 (+179.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.26 -
$1.43
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
33.3%
All Signals
- BEARISH: Price extended above range (+8.4% above its trading range)
- BEARISH: Weak technical setup (31/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.0%)
- BULLISH: Trading 179.6% below Wall St target ($4.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.26 -
$1.43
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.30
Resistance Level
$1.80
Current Trend
Downtrend
Technical data as of
Oct 6, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.31
Wall Street Target
$4.33
(+179.6%)
Revenue Growth (YoY)
21.3%
Profit Margin
-105.2%
PE vs Historical
-8.3 vs 85.2
CHEAP
Share & Embed Analysis
Last updated: October 06, 2026 11:17 PM ET
Data refreshes hourly during market hours. Next update: 12:17 AM
Data refreshes hourly during market hours. Next update: 12:17 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HYFT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
23 analysts |
$84 | 77 BUY |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 68 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
15 analysts |
$52 | 61 BUY |